Prolyl hydroxylase inhibitors and methods of use

Details Prolyl hydroxylase inhibitors and methods of use Prolyl hydroxylase inhibitors and methods of use

2007-06-26

2010-10-12

Schnizer, Richard (Department: 1611)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Cosmetic, antiperspirant, dentifrice

C514S346000, C546S296000, C546S298000

Reexamination Certificate

active

07811595

ABSTRACT:
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

REFERENCES:
patent: 3894920 (1975-07-01), Kondo et al.
patent: 5397799 (1995-03-01), Kress et al.
patent: 5620995 (1997-04-01), Weidmann et al.
patent: 6020350 (2000-02-01), Weidmann et al.
patent: 6566088 (2003-05-01), McKnight et al.
patent: 6589758 (2003-07-01), Zhu
patent: 7183287 (2007-02-01), Durley
patent: 2002/0192737 (2002-12-01), Kaelin, Jr. et al.
patent: 2003/0153503 (2003-08-01), Klaus et al.
patent: 2003/0176317 (2003-09-01), Guenzler-Pukall et al.
patent: 2004/0254215 (2004-12-01), Arend et al.
patent: 2006/0276477 (2006-12-01), Klaus et al.
patent: 2007/0154482 (2007-07-01), Sukhatme et al.
patent: 2007/0213335 (2007-09-01), Fitch et al.
patent: 2008/0124740 (2008-05-01), Evdokimov et al.
patent: 2008/0213404 (2008-09-01), Johnson et al.
patent: 2009/0082357 (2009-03-01), Fitch et al.
patent: WO 97/41103 (1997-11-01), None
patent: WO 02/074980 (2002-09-01), None
patent: WO 02/074981 (2002-09-01), None
patent: WO 03/028663 (2003-04-01), None
patent: WO 2004/035812 (2004-04-01), None
patent: WO 2005/007192 (2005-01-01), None
patent: WO 2005/118836 (2005-12-01), None
patent: WO 2006/114213 (2006-11-01), None
patent: WO 2007/038571 (2007-04-01), None
patent: WO 2007/047194 (2007-04-01), None
patent: WO 2007/070359 (2007-06-01), None
patent: WO 2007/082899 (2007-07-01), None
patent: WO 2007/103905 (2007-09-01), None
patent: WO 2007/136990 (2007-11-01), None
patent: WO 2007/150011 (2007-12-01), None
patent: WO 2008/089051 (2008-07-01), None
patent: WO 2008/089052 (2008-07-01), None
patent: WO 2008/130508 (2008-10-01), None
patent: WO 2008/130527 (2008-10-01), None
patent: WO 2008/137060 (2008-11-01), None
patent: WO 2008/144266 (2008-11-01), None
patent: WO 2009/019656 (2009-02-01), None
patent: WO 2009/037570 (2009-03-01), None
patent: WO 2009/039321 (2009-03-01), None
patent: WO 2009/039323 (2009-03-01), None
patent: WO 2009/043093 (2009-04-01), None
patent: WO 2009/049112 (2009-04-01), None
patent: WO 2009/067790 (2009-06-01), None
patent: WO 2009/070644 (2009-06-01), None
patent: WO 2009/073497 (2009-06-01), None
patent: WO 2009/073669 (2009-06-01), None
patent: WO 2009/086044 (2009-07-01), None
patent: WO 2009/086592 (2009-07-01), None
patent: WO 2009/089547 (2009-07-01), None
Ingersoll et al. Organic Syntheses, CV 2, 328, “Hippuric acid”. (http://web.archive.org/web/20020724135719/http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?prep=cv2p0328, accessed Mar. 11, 2010).
“Hippuric acid sodium salt”. Science Lab.com: Chemicals & Laboratory Equipment. (“http://web.archive.org/web/20041107121553/http://www.sciencelab.com/page/S/PVAR/10415/SLH2620”, accessed Mar. 11, 2010).
Cunliffe et al., “Novel Inhibitors of Prolyl 4-Hydroxylase. 3. Inhibition by the Substrate AnalogueN-Oxaloglycine and Its Derivatives,”J Med. Chem.35:2652-2658 (1992).
Franklin et al., “Approaches to the Design of Anti-Fibrotic Drugs,”Biochem Soc Trans.,19(4):812-5 (Nov. 1991).
Peyssonnaux et al.,“HIF-1α Expression Regulates the Bactericidal Capacity of Phagocytes,”J. Clinical Invest. ,115(7):1806-1815 (Jul. 2005).
Sheehan, “3-Hydroxypicolinic Acid and Some of its Derivatives,”J. Organic Chemistry31(3):636-638 (1996).
Bussolino, “Molecular Mechanisms of Blood Vessel Formation,”Trends Biochem. Sci.,22(7):251-256 (1997).
Folkman et al., “Tumor Angiogenesis,”The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).
Krantz, “Erythropoietin,”Blood, 77:419-434 (1991).
Nguyen et al., “Cellular Interactions in Vascular Growth and Differentiation,”Int. Review of Cytology, 204:1-48 (2001).
O'Reilly et al., “Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,”Cell, 79:315-328 (1994).
O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,”Cell, 88:277-285(1997).
Semenza, “Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis,”Hematol. Oncol. Clin. North Am.,8:863-884 (1994).
Semenza et al., “Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,”J. Biol. Chem.,269:23757-23763 (1994).
Teicher et al., “Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,”Int. J. Cancer, 57:920-925 (1994).
Weidner et al., “Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma,”New Eng. J. Med.,324(1):1-8 (1991).
Bartlett et al., “Molecular Recognition in Chemical and Biological Problems,”Special Pub., Royal Chem. Soc.,78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).
Böhm, “The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,”J. Computer-Aided Molecular Design,6:61-78 (1992).
Elson et al., “Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1α,”Genes&Dev., 15:2520-2532 (2001).
Flower, “Modelling G-protein-coupled receptors for drug design,”Biochimica et Biophysica Acta, 1422:207-234 (1999).
Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,”J Med. Chem.,28(7):849-857 (1985).
Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing,”Proteins: Structure, Function, and Genetics,8:195-202 (1990).
Jones et al., “Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,”J. Mol. Biol.,245:43-53 (1995).
Kaelin, “Proline Hydroxylation and Gene Expression,”Annu. Rev. Biochem.,74:115-125 (2005).
Kuntz et al., “A Geometric Approach to Macromolecule—Ligand Interactions,”J. Mol. Biol.,161:269-288 (1982).
Lee et al., “Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,”JBC, 278:7558-7563 (2003).
Li et al., “PR39, A Peptide Regulator of Angiogenesis,”Nat Med.,6(1):49-55 (2000).
Mancini et al., “Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,”Circulation, 107:294-299 (2003).
McDonough et al., “Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),”PNAS, 103(26):9814-9819 (2006).
Miranker et al., “Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,”Proteins: Structure, Function and Genetics, 11:29-34 (1991).
Nishibata et al., “Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,”Tetrahedron, 47(43):8985-8990 (1991).
Schoneberg et al., “Structural Basis of G Protein-Coupled Receptor Function,”Molecular and Cellular Endocrinology, 151:181-193 (1999).
Semenza, “Signal Transduction to Hypoxia-inducible Factor 1,”Biocehm Pharmacol, 64:993-998 (2002).
Sexton, “Recent advances in our understanding of peptide hormone receptors and RAMPS,”Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).
Vincent et al., “Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1α/VP16 Hybrid Transcription Factor,”Circulation, 102:2255-2261 (2000).
Warnecke et al., “Activation of the Hypoxia

Affiliated with

Also associated with

Rating

Prolyl hydroxylase inhibitors and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prolyl hydroxylase inhibitors and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prolyl hydroxylase inhibitors and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4194309